Cadila Healthcare
Cadila Healthcare is the 5th largest pharmaceutical company in India and is a flagship company of the Ahmedabad based Zydus Cadila Group. It basically deals with pharmaceuticals, diagnostics, herbal products, skin care products, and OTC products.
Cadila Healthcare Ltd. (CADILAHC) possess a market share of 3.85 percent with a turn over of about USD 290 million. The pharmaceutical products of the company comprise of human formulations, veterinary formulations, and bulk drugs.
Cadila Healthcare gained came into power separately from Zydus Cadila Group on May 15, 1995 which went public on 17th July, the same year. The consumer products of Cadila Healthcare include Sugar Free (a low-calorie based tabletop sweetener), a variety of skin care products of Everyuth, and Nutralite. The drugs products of CADILAHC are found in various forms such as tablets, powders and granules, liquids, dry syrups, capsules, injections, and ointments. In 2007, the company launched 39 new products in the Indian market.
Cadila Healthcare has received a range of important certifications which include Medicines Control Council of South Africa and United States Food and Drug Administration. The pharmaceutical market of CADILAHC that belongs to the Medicines Control Council of South Africa estimates around USD 1 billion and the United States Food and Drug Administration unit trades benzonatate tablets and naproxen tablets in a variety of ranges. The company is headed by Mr. Pankaj Patel who is the chairman and Managing Director of the company. Cadila Healthcare Ltd has 9 subsidiaries and 2 joint venture companies which are popularly known as Zydus Atlanta and Sarabhai Zydus. Zydus Atlanta produces intermediates of Pantoprazole and also executes clinical research based on new molecules. The other subsidiary, that is Sarabhai Zydus centers around animal healthcare and is also known to be one of the most leading animal healthcare farms in India.
The global markets of Cadila Healthcare include Sri Lanka, Czechoslovakia, Kenya, Myanmar, Romania, Mauritius, Cambodia, Mauritius and the Russian markets. The registered offices of Cadila Healthcare are located at Zydus Tower, Satellite Cross Roads, Sarkhej-Gandhinagar Highway, Ahmedabad-380015, Gujarat.
Financial Statement of Cadila Healthcare during 2006-07:
Last Updated on 21/06/2011
Cadila Healthcare gained came into power separately from Zydus Cadila Group on May 15, 1995 which went public on 17th July, the same year. The consumer products of Cadila Healthcare include Sugar Free (a low-calorie based tabletop sweetener), a variety of skin care products of Everyuth, and Nutralite. The drugs products of CADILAHC are found in various forms such as tablets, powders and granules, liquids, dry syrups, capsules, injections, and ointments. In 2007, the company launched 39 new products in the Indian market.
Cadila Healthcare has received a range of important certifications which include Medicines Control Council of South Africa and United States Food and Drug Administration. The pharmaceutical market of CADILAHC that belongs to the Medicines Control Council of South Africa estimates around USD 1 billion and the United States Food and Drug Administration unit trades benzonatate tablets and naproxen tablets in a variety of ranges. The company is headed by Mr. Pankaj Patel who is the chairman and Managing Director of the company. Cadila Healthcare Ltd has 9 subsidiaries and 2 joint venture companies which are popularly known as Zydus Atlanta and Sarabhai Zydus. Zydus Atlanta produces intermediates of Pantoprazole and also executes clinical research based on new molecules. The other subsidiary, that is Sarabhai Zydus centers around animal healthcare and is also known to be one of the most leading animal healthcare farms in India.
The global markets of Cadila Healthcare include Sri Lanka, Czechoslovakia, Kenya, Myanmar, Romania, Mauritius, Cambodia, Mauritius and the Russian markets. The registered offices of Cadila Healthcare are located at Zydus Tower, Satellite Cross Roads, Sarkhej-Gandhinagar Highway, Ahmedabad-380015, Gujarat.
Financial Statement of Cadila Healthcare during 2006-07:
- ` 492 million (2006) to ` 664 million (2007) – a rise of 34.96 percent in net profit
- ` 3572 million (2006) to ` 4429 million (2007) – a rise of 23.99 percent in net sales
- ` 3754 million (2006) to ` 4629 million (2007) – a rise of 23.31 percent in total income
Last Updated on 21/06/2011
Major Manufacturing Companies of India
